Find clinical trials

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.

A Phase 1b Study Evaluating the Safety and Tolerability of CLB-4000 with or without Peg-IFNa-2a in Subjects with Chronic Hepatitis B

This study aims to determine whether a new medication, NNC6019-0001, can lower the risk of heart-related complications in people diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease that affects the heart. Participants will be randomly assigned to receive either NNC6019-0001 or a placebo, which contains no active drug. Throughout the study, all participants will continue their standard heart treatments as advised by their healthcare provider.

Rollover study from CLOU064J12301 (AH_238/24) – NOT RECRUITING NEW PARTICIPANTS

At the start of the trial, Patients will have genetic testing and all patients will then receive treatment with Asciminib monotherapy at 80mg daily for the first four weeks, while the genetic results are analysed. Patients are then split into high or standard risks groups based on their genetic results. Patients determined to be at standard risk will continue to receive 80mg daily Asciminib monotherapy while high risk patients will receive combination therapy of: 80mg of Asciminib daily and 50mg of Dasatinib daily. Overall treatment duration is upto 2 years.